Tentative 2024 DUR Board Class Review Schedule Now Available

The 2024 Texas Drug Utilization Review (DUR) Board tentative class review schedule is now available.

When the DUR Board reviews a new drug class, all drugs currently on the market are reviewed for the first time. New drugs to the market falling into one of the drug classes scheduled for review are reviewed under that class. Other drugs that are new to the market and do not fall into one of the drug classes scheduled for review may be reviewed off-cycle. The Board will review new drugs entering the market within 90 days of the meeting at the subsequent meeting.

Jan. 2024

1. ACNE AGENTS, ORAL
2. ACNE AGENTS, TOPICAL
3. ANALGESICS, NARCOTIC – LONG ACTING
4. ANALGESICS, NARCOTIC – SHORT ACTING (NON-PARENTERAL)
5. ANGIOTENSIN MODULATOR COMBINATIONS
6. ANGIOTENSIN MODULATORS
7. ANTIHYPERTENSIVES, SYMPATHOLYTICS
8. ANTIMIGRAINE AGENTS, OTHER
9. ANTIMIGRAINE AGENTS, TRIPTANS
10. ANTIPARKINSON’S AGENTS (ORAL/TRANSDERMAL)
11. BLADDER RELAXANT PREPARATIONS
12. GLUCAGON AGENTS
13. GLUCOCORTICOIDS, INHALED
14. H PYLORI TREATMENT
15. INTRANASAL RHINITIS AGENTS
16. MOVEMENT DISORDERS
17. NEUROPATHIC PAIN
18. ONCOLOGY, ORAL – BREAST
19. ONCOLOGY, ORAL – HEMATOLOGIC
20. ONCOLOGY, ORAL – LUNG
21. ONCOLOGY, ORAL – OTHER
22. ONCOLOGY, ORAL – PROSTATE
23. ONCOLOGY, ORAL – RENAL CELL
24. ONCOLOGY, ORAL – SKIN
25. PAH AGENTS (ORAL, INHALATION)
26. PANCREATIC ENZYMES
27. PHOSPHATE BINDERS
28. PLATELET AGGREGATION INHIBITORS
29. POTASSIUM BINDERS
30. PROGESTINS FOR CACHEXIA
31. PROTON PUMP INHIBITORS (ORAL)
32. SMOKING CESSATION
33. STIMULANTS AND RELATED AGENTS

April 2024

1. ANTI-ALLERGENS, ORAL
2. ANTIBIOTICS, INHALED
3. ANTICOAGULANTS
4. ANTIDEPRESSANTS, OTHER
5. ANTIDEPRESSANTS, SSRIS
6. ANTIDEPRESSANTS, TRICYCLIC
7. ANTIHYPERURICEMICS
8. ANTIVIRALS (ORAL/NASAL)
9. ANXIOLYTICS
10. BETA BLOCKERS (ORAL)
11. BILE SALTS
12. BPH AGENTS
13. BRONCHODILATORS, BETA AGONIST
14. COPD AGENTS
15. COUGH AND COLD AGENTS
16. CYTOKINE AND CAM ANTAGONISTS
17. ERYTHROPOIESIS STIMULATING PROTEINS
18. HEMOPHILIA TREATMENT
19. HEREDITARY ANGIOEDEMA (HAE) TREATMENTS
20. IMMUNE GLOBULINS
21. IMMUNOMODULATORS, ASTHMA
22. IMMUNOMODULATORS, ATOPIC DERMATITIS
23. LINCOSAMIDES/OXAZOLIDINONES/STREPTOGRAMINS
24. LIPOTROPICS, OTHER
25. LIPOTROPICS, STATINS
26. MULTIPLE SCLEROSIS AGENTS
27. PEDIATRIC VITAMIN PREPARATIONS
28. PRENATAL VITAMINS
29. SEDATIVE HYPNOTICS
30. SICKLE CELL ANEMIA TREATMENTS
31. THROMBOPOIESIS STIMULATING PROTEINS
32. UREA CYCLE DISORDER, ORAL

July 2024

1. ALZHEIMER’S AGENTS
2. ANTIHISTAMINES, MINIMALLY SEDATING
3. ANTIPSYCHOTICS
4. CALCIUM CHANNEL BLOCKERS (ORAL)
5. CEPHALOSPORINS AND RELATED ANTIBIOTICS (ORAL)
6. FLUOROQUINOLONES, ORAL
7. GLUCOCORTICOIDS, ORAL
8. IMMUNOMODULATORS, LUPUS
9. IMMUNOSUPPRESSIVES, ORAL/SQ
10. IRON, ORAL
11. LEUKOTRIENE MODIFIERS
12. NSAIDS
13. OPHTHALMIC ANTIBIOTICS
14. OPHTHALMICS ANTIBIOTIC – STEROID COMBINATIONS
15. OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
16. OPHTHALMICS, ANTI-INFLAMMATORIES
17. OPHTHALMICS, ANTI-INFLAMMATORY IMMUNOMODULATORS
18. OPHTHALMICS, GLAUCOMA AGENTS
19. OTIC ANTIBIOTICS
20. OTIC ANTI-INFECTIVES/ANESTHETICS
21. PENICILLINS
22. ROSACEA AGENTS, TOPICAL
23. SKELETAL MUSCLE RELAXANTS
24. STEROIDS, TOPICAL
25. ULCERATIVE COLITIS

Oct. 2024

1. ANDROGENIC AGENTS, TOPICAL
2. ANTIBIOTICS, GASTROINTESTINAL
3. ANTIBIOTICS, TOPICAL
4. ANTIBIOTICS, VAGINAL
5. ANTICONVULSANTS
6. ANTIEMETIC-ANTIVERTIGO AGENTS (EXCLUDES INJECTABLES)
7. ANTIFUNGALS, ORAL
8. ANTIFUNGALS, TOPICAL
9. ANTIHISTAMINES, FIRST GENERATION
10. ANTIPARASITICS, TOPICAL
11. ANTIVIRALS, TOPICAL
12. BONE RESORPTION SUPPRESSION AND RELATED AGENTS
13. COLONY STIMULATING FACTORS
14. EPINEPHRINE, SELF-INJECTED
15. GI MOTILITY, CHRONIC
16. GROWTH HORMONE
17. HEPATITIS C AGENTS
18. HIV/AIDS
19. HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS
20. HYPOGLYCEMICS, INSULIN
21. HYPOGLYCEMICS, MEGLITINIDES
22. HYPOGLYCEMICS, METFORMIN
23. HYPOGLYCEMICS, SGLT2
24. HYPOGLYCEMICS, TZD
25. MACROLIDES-KETOLIDES
26. OPIATE DEPENDENCE TREATMENTS
27. TETRACYCLINES